Cargando…
Enhancement of viability of radiosensitive (PBMC) and resistant (MDA-MB-231) clones in low-dose-rate cobalt-60 radiation therapy
OBJECTIVE: In the present study, the authors investigated the in vitro behavior of radio-resistant breast adenocarcinoma (MDA-MB-231) cells line and radiosensitive peripheral blood mononuclear cells (PBMC), as a function of different radiation doses, dose rates and postirradiation time kinetics, wit...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Colégio Brasileiro de Radiologia e Diagnóstico por
Imagem
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492568/ https://www.ncbi.nlm.nih.gov/pubmed/26185342 http://dx.doi.org/10.1590/0100-3984.2014.0022 |
_version_ | 1782379784929542144 |
---|---|
author | Falcão, Patrícia Lima Motta, Bárbara Miranda de Lima, Fernanda Castro Lima, Celso Vieira Campos, Tarcísio Passos Ribeiro |
author_facet | Falcão, Patrícia Lima Motta, Bárbara Miranda de Lima, Fernanda Castro Lima, Celso Vieira Campos, Tarcísio Passos Ribeiro |
author_sort | Falcão, Patrícia Lima |
collection | PubMed |
description | OBJECTIVE: In the present study, the authors investigated the in vitro behavior of radio-resistant breast adenocarcinoma (MDA-MB-231) cells line and radiosensitive peripheral blood mononuclear cells (PBMC), as a function of different radiation doses, dose rates and postirradiation time kinetics, with a view to the interest of clinical radiotherapy. MATERIALS AND METHODS: The cells were irradiated with Co-60, at 2 and 10 Gy and two different exposure rates, 339.56 cGy.min(–1) and the other corresponding to one fourth of the standard dose rates, present over a 10-year period of cobalt therapy. Post-irradiation sampling was performed at pre-established kinetics of 24, 48 and 72 hours. The optical density response in viability assay was evaluated and a morphological analysis was performed. RESULTS: Radiosensitive PBMC showed decrease in viability at 2 Gy, and a more significant decrease at 10 Gy for both dose rates. MDAMB- 231 cells presented viability decrease only at higher dose and dose rate. The results showed MDA-MB-231 clone expansion at low dose rate after 48–72 hours post-radiation. CONCLUSION: Low dose rate shows a possible potential clinical impact involving decrease in management of radio-resistant and radiosensitive tumor cell lines in cobalt therapy for breast cancer. |
format | Online Article Text |
id | pubmed-4492568 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Colégio Brasileiro de Radiologia e Diagnóstico por
Imagem |
record_format | MEDLINE/PubMed |
spelling | pubmed-44925682015-07-16 Enhancement of viability of radiosensitive (PBMC) and resistant (MDA-MB-231) clones in low-dose-rate cobalt-60 radiation therapy Falcão, Patrícia Lima Motta, Bárbara Miranda de Lima, Fernanda Castro Lima, Celso Vieira Campos, Tarcísio Passos Ribeiro Radiol Bras Original Articles OBJECTIVE: In the present study, the authors investigated the in vitro behavior of radio-resistant breast adenocarcinoma (MDA-MB-231) cells line and radiosensitive peripheral blood mononuclear cells (PBMC), as a function of different radiation doses, dose rates and postirradiation time kinetics, with a view to the interest of clinical radiotherapy. MATERIALS AND METHODS: The cells were irradiated with Co-60, at 2 and 10 Gy and two different exposure rates, 339.56 cGy.min(–1) and the other corresponding to one fourth of the standard dose rates, present over a 10-year period of cobalt therapy. Post-irradiation sampling was performed at pre-established kinetics of 24, 48 and 72 hours. The optical density response in viability assay was evaluated and a morphological analysis was performed. RESULTS: Radiosensitive PBMC showed decrease in viability at 2 Gy, and a more significant decrease at 10 Gy for both dose rates. MDAMB- 231 cells presented viability decrease only at higher dose and dose rate. The results showed MDA-MB-231 clone expansion at low dose rate after 48–72 hours post-radiation. CONCLUSION: Low dose rate shows a possible potential clinical impact involving decrease in management of radio-resistant and radiosensitive tumor cell lines in cobalt therapy for breast cancer. Colégio Brasileiro de Radiologia e Diagnóstico por Imagem 2015 /pmc/articles/PMC4492568/ /pubmed/26185342 http://dx.doi.org/10.1590/0100-3984.2014.0022 Text en © Colégio Brasileiro de Radiologia e Diagnóstico por Imagem http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Falcão, Patrícia Lima Motta, Bárbara Miranda de Lima, Fernanda Castro Lima, Celso Vieira Campos, Tarcísio Passos Ribeiro Enhancement of viability of radiosensitive (PBMC) and resistant (MDA-MB-231) clones in low-dose-rate cobalt-60 radiation therapy |
title | Enhancement of viability of radiosensitive (PBMC) and resistant
(MDA-MB-231) clones in low-dose-rate cobalt-60 radiation therapy |
title_full | Enhancement of viability of radiosensitive (PBMC) and resistant
(MDA-MB-231) clones in low-dose-rate cobalt-60 radiation therapy |
title_fullStr | Enhancement of viability of radiosensitive (PBMC) and resistant
(MDA-MB-231) clones in low-dose-rate cobalt-60 radiation therapy |
title_full_unstemmed | Enhancement of viability of radiosensitive (PBMC) and resistant
(MDA-MB-231) clones in low-dose-rate cobalt-60 radiation therapy |
title_short | Enhancement of viability of radiosensitive (PBMC) and resistant
(MDA-MB-231) clones in low-dose-rate cobalt-60 radiation therapy |
title_sort | enhancement of viability of radiosensitive (pbmc) and resistant
(mda-mb-231) clones in low-dose-rate cobalt-60 radiation therapy |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492568/ https://www.ncbi.nlm.nih.gov/pubmed/26185342 http://dx.doi.org/10.1590/0100-3984.2014.0022 |
work_keys_str_mv | AT falcaopatricialima enhancementofviabilityofradiosensitivepbmcandresistantmdamb231clonesinlowdoseratecobalt60radiationtherapy AT mottabarbaramiranda enhancementofviabilityofradiosensitivepbmcandresistantmdamb231clonesinlowdoseratecobalt60radiationtherapy AT delimafernandacastro enhancementofviabilityofradiosensitivepbmcandresistantmdamb231clonesinlowdoseratecobalt60radiationtherapy AT limacelsovieira enhancementofviabilityofradiosensitivepbmcandresistantmdamb231clonesinlowdoseratecobalt60radiationtherapy AT campostarcisiopassosribeiro enhancementofviabilityofradiosensitivepbmcandresistantmdamb231clonesinlowdoseratecobalt60radiationtherapy |